Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, December 02 2020 - 23:00
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
FRANKLIN LAKES, N.J., December 2, 2020 /PRNewswire-AsiaNet/ --

- Investment includes new manufacturing facility in Europe

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical 
technology company, today announced plans to invest approximately $1.2 billion 
over a 4-year period to expand and upgrade manufacturing capacity and 
technology for pre-fillable syringes (PFS) and advanced drug delivery systems 
(ADDS) across its six global manufacturing locations and add a new 
manufacturing facility in Europe. 

    The new manufacturing facility in Europe is expected to be operational by 
the end of 2023. The investment will also fund capacity expansion, new product 
innovations, manufacturing technology enhancements and business continuity 
improvements across its existing network, all designed to maximize supply and 
reduce risks for pharmaceutical companies that rely on ready-to-fill syringes 
for their injectable drugs — including complex biologics, vaccines and small 

    "BD invented the ready-to-fill pre-fillable syringe technology, and today's 
announcement demonstrates our continued commitment to better serve our 
customers," said Eric Borin, worldwide president of BD Pharmaceutical Systems. 
"Since 2018, BD has added 350 million units of manufacturing capacity for glass 
barrel pre-fillable syringes, and this new commitment will invest in additional 
upgrades at all of our Pharmaceutical Systems manufacturing facilities and 
across multiple product categories. In addition, this investment positions BD 
to have the needed surge capacity for increased pre-fillable syringe demand 
during times of pandemic response or periods of significant growth of new 
injectable drugs and vaccines. This significant investment in one of BD's 
fastest growing business units will further advance our leadership position and 
enable continued strong growth in the years ahead."

    The six current manufacturing facilities for BD Pharmaceutical Systems that 
will see a portion of this investment include facilities in Columbus, Nebraska; 
Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United 
Kingdom; and Tatabánya, Hungary.  

About BD

    BD is one of the largest global medical technology companies in the world 
and is advancing the world of health by improving medical discovery, 
diagnostics and the delivery of care. The company supports the heroes on the 
frontlines of health care by developing innovative technology, services and 
solutions that help advance both clinical therapy for patients and clinical 
process for health care providers. BD and its 65,000 employees have a passion 
and commitment to help enhance the safety and efficiency of clinicians' care 
delivery process, enable laboratory scientists to accurately detect disease and 
advance researchers' capabilities to develop the next generation of diagnostics 
and therapeutics. BD has a presence in virtually every country and partners 
with organizations around the world to address some of the most challenging 
global health issues. By working in close collaboration with customers, BD can 
help enhance outcomes, lower costs, increase efficiencies, improve safety and 
expand access to health care. For more information on BD, please visit 


    Troy Kirkpatrick                                                        
    BD Public Relations                                                    

    Kristen M. Stewart, CFA
    BD Investor Relations


    Source: BD (Becton, Dickinson and Company)